Subscribe & Follow

Advertise your job vacancies

Pembrolizumab gets regulatory go-ahead

MSD's cancer drug, Pembrolizumab, has received regulatory approval by the Medicines Control Council (now South African Health Products Regulatory Authority) in South Africa.

17 Nov 2017

Photo: Mims

This followed agreement with the Department of Health that the application complied with the criteria for fast-track review. Breakthroughs in immuno- oncology provide healthcare practitioners and patients with new options to treat cancer that did not exist before.

MSD has an extensive immuno-oncology clinical research programme, which currently involves more than 550 trials studying Pembrolizumab across a wide variety of cancers and treatment settings. MSD is currently working on making Pembrolizumab (trade name Keytruda) available to patients in early 2018.